Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04910022 · ClinicalTrials.gov registry record · Phase 1
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
A Phase 1 study of Glioblastoma and Diffuse Glioma, sponsored by Nerviano Medical Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 18
- Study locations
NCT04910022: Active Phase 1 study of Glioblastoma and Diffuse Glioma, sponsored by Nerviano Medical Sciences.
NCT04910022 is a Phase 1 study of Glioblastoma and Diffuse Glioma that is active but no longer recruiting, run by Nerviano Medical Sciences. The registered enrollment target is 150 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (39% higher). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04910022, a Phase 1 study of Glioblastoma and Diffuse Glioma, is active but no longer recruiting, sponsored by Nerviano Medical Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 18
- Study locations
Study Summary
Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG NMS-03305293
Study Locations (18)
Other
- IRCCS Istituto delle Scienze Neurologiche di Bologna - Bologna
- IRCCS Istituto Neurologico Carlo Besta - Milan
- Istituto Oncologico Veneto - IRCCS - Padua
- Istituto Clinico Humanitas - Rozzano
- Erasmus Medical Center - Rotterdam
- PanOncology Trials (Pan American Center for Oncology Trials, LLC) - Rio Piedras
- University Hospital Zurich - Zurich
Texas
- UT Southwestern Medical Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Arizona
- Mayo Clinic Hospital - Phoenix - Phoenix
California
- University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center - Orange
Florida
- Mayo Clinic Florida - Jacksonville
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Cancer Center - Rochester
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2027-09-07 |
| Phase | Phase 1 |
What the registry record for NCT04910022 still lists
NCT04910022 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (39% higher).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT04910022 lists 18 locations in 11 states (Other, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT04910022 about?
NCT04910022 is a clinical study titled "Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma". Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.
What is the current status of trial NCT04910022?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2021-12-01. Estimated completion is 2027-09-07.
What conditions does trial NCT04910022 study?
This clinical trial studies the following conditions: Glioblastoma, Diffuse Glioma.
What interventions are being tested in trial NCT04910022?
The interventions under investigation include: Temozolomide (DRUG), NMS-03305293 (DRUG).
Who is sponsoring clinical trial NCT04910022?
This trial is sponsored by Nerviano Medical Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04910022 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04910022's enrollment target sits among peer trials
150 32nd of 199 higher than 168 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI